ClinicalTrials.gg
RecruitingNCT07702032Updated Nov 3, 2026

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

A Phase 3 interventional study of Petosemtamab and Cetuximab in Left-sided Colorectal Cancer, sponsored by Genmab. Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 3, 2026First site in Australia6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
158th of 1,932
960 · median 64
Started
2026
with 117 others
Phase 3
117 of 2,339
16 open now
Primary completion
2029-07
later than 548 of 628 live
Registered
2,305th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 158th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 118 that started in 2026, is one of 117 in phase 3, reaches primary completion later than 548 of the 628 other live ones, and was the 2,305th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body.

Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo.

The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Read the detailed description

This Phase 3, randomized, open-label, global trial is designed to assess the efficacy and safety of petosemtamab plus investigator's choice (IC) chemotherapy (fluorouracil + leucovorin (calcium folinate) + oxaliplatin [mFOLFOX6] or fluorouracil + leucovorin (calcium folinate) + irinotecan [FOLFIRI]) versus standard of care (SOC) (ie, cetuximab + IC chemotherapy [mFOLFOX6 or FOLFIRI]) as 1L therapy in participants with unresectable or metastatic left-sided colorectal cancer.

03

Conditions studied

  • Left-sided Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed left-sided colorectal adenocarcinoma that is unresectable or .
  • Must have documented KRAS and NRAS wild type (wt) colorectal cancer (CRC), as determined by medical record of results from local testing or as assessed by central testing. Local testing must have been conducted in accordance with local guidelines using an Food and Drug Administration (FDA)-approved test or a laboratory-developed test that is validated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States). Next-generation sequencing (NGS)-based test results from tumor tissue are required for determining eligibility. Polymerase chain reaction (PCR)-based tests, sanger sequencing, or pyrosequencing test results are not allowed.
  • Has not received any prior systemic therapy for unresectable or metastatic CRC.
  • Must be eligible for treatment with mFOLFOX6 (if assigned to receive mFOLFOX6) or FOLFIRI (if assigned to receive FOLFIRI) according to local regulatory approvals and SOC guidelines.

Key Exclusion Criteria:

  • BRAF mutation, and/or microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) and/or protocol specified tumor status as documented by local test results in the medical record or from central testing or known documented activating HRAS mutation identified prior to enrollment from local testing results in the medical record, if available.
  • Prior exposure to any agents that target epidermal growth factor receptor (EGFR) (including but not limited to protein products, monoclonal antibodies, tyrosine kinase inhibitors, or antisense oligonucleotide therapy).
  • Known complete dihydropyrimidine dehydrogenase (DPD) deficiency or known homozygous/compound heterozygous dihydropyrimidine dehydrogenase gene (DPYD) variants associated with complete loss of DPD activity. Testing for DPD deficiency should be performed per local guidelines.
  • For a participant who is to receive FOLFIRI: known to be homozygous for the UGT1A1*28 or *6 alleles or compound or double heterozygous for the UGT1A1*28 and *6 alleles. Testing for UGT1A1 should be done in accordance with local guidelines.
  • Participants with non-colorectal adenocarcinomatous disease.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    Petosemtamab + IC Chemotherapy

    Participants will receive petosemtamab and IC chemotherapy (mFOLFOX6 or FOLFIRI).

    Drug: Petosemtamab · Drug: FOLFIRI · Drug: mFOLFOX6

  • Active comparator
    Cetuximab + IC Chemotherapy

    Participants will receive cetuximab + IC chemotherapy (mFOLFOX6 or FOLFIRI).

    Drug: Cetuximab · Drug: FOLFIRI · Drug: mFOLFOX6

Interventions

  • Intravenous infusion

  • Intravenous infusion

  • DrugFOLFIRI

    Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.

  • DrugmFOLFOX6

    Fluorouracil + leucovorin (calcium folinate) + oxaliplatin via intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)

    Time frame: Up to approximately 35 months

  2. Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 35 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 62 months

  2. Duration of Response (DOR) per RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 62 months

  3. Disease Control Rate (DCR) per RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 62 months

  4. Progression-free Survival after First Subsequent Therapy (PFS2)

    Time frame: Up to approximately 62 months

  5. Curative Resection (R0) Rate

    Time frame: Up to approximately 62 months

  6. Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 62 months

  7. Change from Baseline in Symptoms and Functioning, as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire (QLQ)-F17

    Time frame: Baseline up to approximately 62 months

  8. Change from Baseline in Symptoms and Functioning, as Measured by EORTC QLQ-CR29

    Time frame: Baseline up to approximately 62 months

  9. Time to Worsening in Symptoms and Functioning, as Measured by EORTC QLQ-F17

    Time frame: Up to approximately 62 months

  10. Time to Worsening in Symptoms and Functioning, as Measured by EORTC QLQ-CR29

    Time frame: Up to approximately 62 months

  11. Overall Side Effect Burden, as Measured by EORTC Item 168

    Time frame: Up to approximately 62 months

07

Study locations

12 of 12 sites recruiting
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
    Recruiting
  • Valkyrie Clinical Trials - Los Angeles
    Los Angeles, California 90067, United States
    Recruiting
  • Low Country Cancer Care Associates_Savannah_1
    Savannah, Georgia 31405, United States
    Recruiting
  • Central Georgia Cancer Care - Warner Robins Office
    Warner Robins, Georgia 31088, United States
    Recruiting
  • Hematology-Oncology of Indiana, P.C.
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Oncology Hematology Associates - Springfield_Springfield_2
    Springfield, Missouri 65807, United States
    Recruiting
  • Washington University Saint Louis
    St Louis, Missouri 63110, United States
    Recruiting
  • New York Cancer and Blood Specialists - Babylon Medical Oncology
    Babylon, New York 11702, United States
    Recruiting
  • Vista Oncology
    Olympia, Washington 98502, United States
    Recruiting
  • GenesisCare - Campbelltown CAMPBELLTOWN
    Campbelltown, New South Wales 2560, Australia
    Recruiting
  • GenesisCare - St Andrew's ADELAIDE
    Adelaide, South Australia 5000, Australia
    Recruiting
  • PanOncology
    Manati, PR 00674, Puerto Rico
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2029, 35 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 35 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 14, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Sep 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Australia
Show 6 added (4 United States, 2 Australia)
  • Genesis Cancer Center · Hot Springs, United States
  • Valkyrie Clinical Trials - Los Angeles · Los Angeles, United States
  • Washington University Saint Louis · St Louis, United States
  • New York Cancer and Blood Specialists - Babylon Medical Oncology · Babylon, United States
  • GenesisCare - Campbelltown CAMPBELLTOWN · Campbelltown, Australia
  • GenesisCare - St Andrew's ADELAIDE · Adelaide, Australia
across 2 updates, Oct 6, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    4 sites added — first site in Australia
    Show 4 added (2 United States, 2 Australia)
    • Washington University Saint Louis · St Louis, United States
    • New York Cancer and Blood Specialists - Babylon Medical Oncology · Babylon, United States
    • GenesisCare - Campbelltown CAMPBELLTOWN · Campbelltown, Australia
    • GenesisCare - St Andrew's ADELAIDE · Adelaide, Australia
    + 1 other change: verification date
  2. Oct 6, 2026
    2 sites added
    Show 2 added (2 United States)
    • Genesis Cancer Center · Hot Springs, United States
    • Valkyrie Clinical Trials - Los Angeles · Los Angeles, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07702032
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Aug 11, 2026
Primary completion
Jul 2029 (estimated)
Completion
Sep 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petosemtamab

Start the discussion